NextCure, Inc. - Common Stock (OQ:NXTC)

Mar 21, 2024 08:55 am ET
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer today provided a business update and reported full year 2023...
Mar 05, 2024 08:05 am ET
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a...
Jan 18, 2024 04:05 pm ET
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of...
Dec 21, 2023 07:05 am ET
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a...
Dec 14, 2023 06:45 am ET
NextCure Provides Year-End Clinical Pipeline Updates
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical...
Nov 20, 2023 07:00 am ET
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
Nov 15, 2023 04:05 pm ET
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a...
Nov 02, 2023 04:05 pm ET
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported...
Oct 17, 2023 08:05 am ET
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of new...
Sep 26, 2023 04:05 pm ET
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, including neuroinflammatory disease, today...
Sep 12, 2023 08:05 am ET
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of Phase 2...
Sep 07, 2023 04:05 pm ET
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a review...
Sep 05, 2023 04:05 pm ET
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of...
Aug 31, 2023 07:00 am ET
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
Aug 03, 2023 04:05 pm ET
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported...
Jun 21, 2023 04:05 pm ET
NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of a poster...
May 09, 2023 07:00 am ET
NextCure to Present at the JMP Securities Life Sciences Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
May 04, 2023 04:05 pm ET
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported...
Apr 11, 2023 07:00 am ET
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Mar 02, 2023 04:05 pm ET
NextCure Provides Business Update and Reports Full Year 2022 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided a business update and reported...
Feb 07, 2023 07:00 am ET
NextCure to Present at SVB Securities Global Biopharma Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Nov 22, 2022 08:00 am ET
NextCure to Present at Upcoming Investor Conferences
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Nov 15, 2022 04:30 pm ET
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets. The...
Nov 07, 2022 08:05 am ET
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial...
Nov 03, 2022 04:15 pm ET
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update and reported third...
Nov 03, 2022 09:15 am ET
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial...
Oct 27, 2022 04:05 pm ET
NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M....
Oct 05, 2022 08:15 am ET
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced two presentations at the...
Oct 04, 2022 04:05 pm ET
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase...
Sep 22, 2022 08:00 am ET
NextCure to Present at the Ladenburg Thalmann Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Aug 04, 2022 04:05 pm ET
NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2022 financial...
Jul 06, 2022 08:00 am ET
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper...
Jun 27, 2022 08:00 am ET
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, presented in vivo data at the 2022 ECM...
Jun 22, 2022 08:00 am ET
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that collaborator Brahm...
Jun 08, 2022 08:00 am ET
NextCure to Present at the JMP Securities Life Sciences Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
May 05, 2022 04:05 pm ET
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2022 financial...
May 03, 2022 08:00 am ET
NextCure to Present at the BofA Securities 2022 Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
Apr 19, 2022 07:30 am ET
NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper...
Apr 05, 2022 08:00 am ET
NextCure to Present at 21st Annual Needham Virtual Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Mar 03, 2022 04:05 pm ET
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year...
Feb 08, 2022 08:00 am ET
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Dec 13, 2021 08:05 am ET
NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data in oral and poster...
Nov 30, 2021 08:00 am ET
NextCure to Present at The JMP Securities Hematology and Oncology Summit
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
Nov 22, 2021 08:00 am ET
NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in...
Nov 13, 2021 02:00 pm ET
NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical...
Nov 04, 2021 04:05 pm ET
NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2021 financial...
Nov 04, 2021 09:15 am ET
NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two...
Nov 01, 2021 08:00 am ET
NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a...
Oct 19, 2021 08:05 am ET
NextCure Announces Three New Members of its Scientific Advisory Board
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Elizabeth...
Oct 07, 2021 04:05 pm ET
NextCure Announces Publication of Preclinical Data for NC410
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of...
Oct 04, 2021 08:05 am ET
NextCure Announces New Appointments to its Board of Directors
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G....
Oct 01, 2021 08:45 am ET
NextCure to Give Three Presentations at Society for Immunotherapy of Cancer Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two...
Sep 07, 2021 07:00 am ET
NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Sep 02, 2021 07:00 am ET
NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
Aug 05, 2021 04:05 pm ET
NextCure Reports Second Quarter 2021 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2021 financial...
Jul 06, 2021 04:05 pm ET
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical...
Jun 21, 2021 04:05 pm ET
NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the...
Jun 10, 2021 04:10 pm ET
NextCure to Present at the JMP Securities Life Sciences Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
May 19, 2021 06:05 pm ET
NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial...
May 06, 2021 05:15 pm ET
NextCure Reports First Quarter 2021 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2021 financial...
May 05, 2021 04:10 pm ET
NextCure to Present at the BofA Securities 2021 Virtual Health Care Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
Apr 28, 2021 04:10 pm ET
NextCure to Present at the 7th Annual Truist Securities Life Sciences Summit
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
Apr 10, 2021 08:30 am ET
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and...
Apr 07, 2021 04:05 pm ET
NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Mar 04, 2021 04:05 pm ET
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year...
Mar 02, 2021 04:05 pm ET
REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual...
Feb 26, 2021 04:15 pm ET
NextCure to Host Virtual R&D Update Event on March 4, 2021
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual...
Jan 28, 2021 10:00 am ET
LONG-TERM SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, Jan. 28, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. ("NextCure" or "the Company") (NASDAQ: NXTC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jan 27, 2021 08:33 am ET
LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “the Company”) (NASDAQ:
Jan 14, 2021 04:05 pm ET
Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han...
Dec 18, 2020 01:48 pm ET
LONG-TERM SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “the Company”) (NASDAQ:
Dec 17, 2020 07:05 am ET
NextCure Provides Updates on NC318 Clinical Program
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical...
Nov 26, 2020 03:24 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NextCure, Inc. - NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Nov 23, 2020 04:05 pm ET
NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a...
Nov 22, 2020 03:24 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. - NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Nov 20, 2020 08:28 am ET
NXTC CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i)  purchased or acquired the securities of NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) securities between November 5, 2019 to July 14, 2020; and  (ii) purchased or acquired NextCure common stock pursuant to or traceable to the Company's Registration Statement on Form S-1 which was filed with and declared effective by the SEC
Nov 18, 2020 11:06 am ET
NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...
Nov 17, 2020 11:30 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NextCure, Inc. (NXTC)
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ:
Nov 16, 2020 10:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. - NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Nov 16, 2020 11:15 am ET
DEADLINE ALERT for FLDM, GOCO, and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 14, 2020 01:00 pm ET
ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contac
NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the "Class Period"); and/or (2) pursuant or traceable to NextCure's November 2019 secondary public offering of the important November 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for NextCure investors under the federal securities laws.
Nov 13, 2020 12:00 pm ET
DEADLINE ALERT for GOCO, NXTC, WRTC, GLNG: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 11, 2020 04:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. - NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Nov 11, 2020 02:50 pm ET
NXTC STOCK ALERT: Zhang Investor Law Announces Securities Class Action Lawsuit Against NextCure, Inc. – NXTC
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of NextCure, Inc. (NASDAQ: NXTC) (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant or traceable to...
Nov 11, 2020 12:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NextCure, Inc. (NXTC)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased NextCure, Inc. (“NextCure” or the Company”) (NASDAQ:...
Nov 10, 2020 04:17 pm ET
NXTC CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i)  purchased or acquired the securities of NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) securities between November 5, 2019 to July 14, 2020; and  (ii) purchased or acquired NextCure common stock pursuant to or traceable to the Company's Registration Statement on Form S-1 which was filed with and declared effective by the SEC
Nov 10, 2020 04:00 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action – NXTC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant or traceable to NextCure’s...
Nov 09, 2020 11:00 am ET
DEADLINE ALERT for FLDM, GOCO, and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 06, 2020 11:07 am ET
SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against NextCure, Inc.– NXTC; IMPORTANT NOV. 20 DEADLINE –NXTC
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of NextCure, Inc. (NASDAQ: NXTC) (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant...
Nov 05, 2020 04:27 pm ET
NextCure Reports Third Quarter 2020 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2020 financial...
Nov 05, 2020 03:47 pm ET
NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...
Nov 05, 2020 12:30 pm ET
DEADLINE ALERT for GOCO, NXTC, WRTC, GLNG: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 05, 2020 09:30 am ET
LAWSUITS FOR SECURITIES VIOLATIONS FILED AGAINST GOCO, NXTC, AND ACB: Block & Leviton LLP Reminds Investors of Class Actions for Violations of the Federal Securities Laws
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that securities class actions have been filed against GoHealth, Inc. (NASDAQ: GOCO), NextCure, Inc. (NASDAQ: NXTC), and Aurora Cannabis Inc. (NYSE:...
Nov 03, 2020 06:15 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact the Firm – NX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant or traceable to NextCure’s November 2019 secondary public offering of the important November 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for NextCure investors under the federal securities laws.
Nov 03, 2020 11:00 am ET
DEADLINE ALERT for FLDM, GOCO, and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 30, 2020 08:45 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds NextCure, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – NXTC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant or traceable to NextCure’s...
Oct 30, 2020 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NextCure, Inc. (NXTC)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased NextCure, Inc. (“NextCure” or the Company”) (NASDAQ:...
Oct 29, 2020 03:03 pm ET
NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...
Oct 28, 2020 08:38 pm ET
ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm -
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the "Class Period"); and/or (2) pursuant or traceable to NextCure's November 2019 secondary public offering of the important November 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for NextCure investors under the federal securities laws.
Oct 28, 2020 04:30 pm ET
LAWSUITS FOR SECURITIES VIOLATIONS FILED AGAINST GOCO, NXTC, AND ACB: Block & Leviton LLP Reminds Investors of Class Actions for Violations of the Federal Securities Laws
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that securities class actions have been filed against GoHealth, Inc. (NASDAQ: GOCO), NextCure, Inc. (NASDAQ: NXTC), and Aurora Cannabis Inc. (NYSE:...
Oct 28, 2020 12:30 pm ET
DEADLINE ALERT for GOCO, NXTC, WRTC, GLNG: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 27, 2020 04:16 pm ET
NXTC CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i)  purchased or acquired the securities of NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) securities between November 5, 2019 to July 14, 2020; and  (ii) purchased or acquired NextCure common stock pursuant to or traceable to the Company's Registration Statement on Form S-1 which was filed with and declared effective by the SEC
Oct 27, 2020 12:00 pm ET
DEADLINE ALERT for FLDM, GOCO, and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 26, 2020 08:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. - NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 23, 2020 10:23 am ET
NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...
Oct 22, 2020 05:45 pm ET
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Co
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant or traceable to NextCure’s...
Oct 22, 2020 11:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NextCure, Inc. (NXTC)
LOS ANGELES, Oct. 22, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased NextCure, Inc. ("NextCure" or the Company") (NASDAQ: NXTC) (a) securities between November 5, 2019 and July 14, 2020, inclusive (the "Class Period"); and/or (b) common stock pursuant or traceable to the Company's November 2019 secondary public offering ("SPO" or the "Offering").
Oct 21, 2020 07:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. - NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 21, 2020 01:00 pm ET
NXTC, FLDM & WRTC Class Action Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Upcoming Lead Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 21, 2020 12:00 pm ET
DEADLINE ALERT for GOCO and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 20, 2020 11:00 am ET
DEADLINE ALERT for GOCO, NXTC, WRTC, GLNG: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 15, 2020 05:15 pm ET
ROSEN, A LEADING AND RANKED FIRM, Reminds NextCure, Inc. Investors of Important Deadline in Securities Class Action – NXTC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant or traceable to NextCure’s...
Oct 15, 2020 02:19 pm ET
DEADLINE ALERT for FLDM, GOCO, and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 15, 2020 11:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NextCure, Inc. (NXTC)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased NextCure, Inc. (“NextCure” or the Company”) (NASDAQ:...
Oct 14, 2020 01:16 pm ET
NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...
Oct 13, 2020 01:46 pm ET
NXTC CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
NEW YORK, Oct. 13, 2020 /PRNewswire/ --Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i)  purchased or acquired the securities of NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) securities between November 5, 2019 to July 14, 2020; and  (ii) purchased or acquired NextCure common stock pursuant to or traceable to the Company's Registration Statement on Form S-1 which was filed with and declared effective by the SEC o
Oct 12, 2020 11:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. - NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 12, 2020 12:00 pm ET
DEADLINE ALERT for GOCO, NXTC, WRTC, GLNG: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 09, 2020 12:04 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. - NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 08, 2020 07:35 pm ET
Portnoy Law: Lawsuit Filed On Behalf of Nextcure, Inc. Investors
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Nextcure, Inc. ("Nextcure" or "the Company") (NASDAQ: NXTC) investors that acquired securities between November 5, 2019 and July 14, 2020. Investors are...
Oct 08, 2020 11:30 am ET
DEADLINE ALERT for NNOX, FLDM, and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 08, 2020 08:00 am ET
LAWSUITS FOR SECURITIES VIOLATIONS FILED AGAINST NXTC AND WRTC: Block & Leviton LLP Reminds Investors of Class Actions for Violations of the Federal Securities Laws
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that securities class actions have been filed against NextCure, Inc. (NASDAQ: NXTC) and Wrap Technologies, Inc. (NASDAQ: WRTC). Shareholders...
Oct 07, 2020 10:09 am ET
NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...
Oct 06, 2020 07:15 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Reminds NextCure, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant or traceable to NextCure’s...
Oct 05, 2020 07:20 pm ET
ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (2) pursuant or traceable to NextCure’s November 2019 secondary public offering of the important November 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for NextCure investors under the federal securities laws.
Oct 02, 2020 11:45 am ET
DEADLINE ALERT for FLDM, GOCO, and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 02, 2020 11:00 am ET
NXTC Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NextCure, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NextCure, Inc. ("NextCure” or "the Company") (NASDAQ:NXTC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired NextCure securities: (1) between November 5, 2019 and July 13, 2020, inclusive (the "Class Period"); and (2) pursuant or traceable to the Company’s Registration Statement and Prospectus filed with the SEC on November 12 and 18, 2019. Such investors are encouraged to join this case by visiting the firm’s site:
Oct 01, 2020 12:00 pm ET
DEADLINE REMINDER: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NextCure, Inc. (NXTC) on Behalf of Investors
Law Offices of Howard G. Smith reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) (a) securities between November 5, 2019 and July 14, 2020, inclusive (the “Class Pe
Oct 01, 2020 08:45 am ET
LAWSUITS FOR SECURITIES VIOLATIONS FILED AGAINST NXTC AND WRTC: Block & Leviton LLP Reminds Investors of Class Actions for Violations of the Federal Securities Laws
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that securities class actions have been filed against NextCure, Inc. (NASDAQ: NXTC) and Wrap Technologies, Inc. (NASDAQ: WRTC). Shareholders...
Sep 30, 2020 06:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NextCure, Inc. – NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Sep 30, 2020 11:11 am ET
NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...
Sep 29, 2020 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action of a Securities Class Action Lawsuit Against NextCure, Inc. (NXTC)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased NextCure, Inc. (“NextCure” or the Company”) (NASDAQ:
Sep 28, 2020 10:29 am ET
NXTC SHAREHOLDER ALERT: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the securities of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) securities between November 5, 2019 to July 14, 2020; and (ii) purchased or acquired NextCure common stock pursuant to or traceable to the Company's Registration Statement on Form S-1 which was filed with and declared effective by the SEC on November 12, and November 14, 2019. The l
Sep 27, 2020 02:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. - NXTC
Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Sep 25, 2020 07:00 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against NextCure, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the “Class...
Sep 25, 2020 10:42 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “the Company”) (NASDAQ:
Sep 25, 2020 10:02 am ET
NXTC SHAREHOLDER ALERT: Bernstein Liebhard Announces that a Securities Class Action Lawsuit has Been Filed Against NextCure Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that: (i) purchased or acquired the securities of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) securities between November 5, 2019 to July 14, 2020; and (ii) purchased or acquired NextCure common stock pursuant to or traceable to the Company's REgistration Statement on Form S-1 which was filed with and declared effective by the SEC on November 12, and November 14, 2019. The lawsuit filed in the United States District Court for the So
Sep 25, 2020 10:00 am ET
NXTC Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NextCure, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NextCure, Inc. ("NextCure” or "the Company") (NASDAQ: NXTC) and certain of its officers, on behalf of shareholders who...
Sep 24, 2020 04:17 pm ET
Shareholder Alert: Robbins LLP Announces That An Investor of NextCure, Inc. (NXTC ) Filed a Class Action Complaint Against the Company
Shareholder rights law firm Robbins LLP announces that an investor of NextCure, Inc. (NASDAQ: NXTC) filed a class action against the Company for: (i) alleged violations of the Securities Exchange Act of 1934 between November 5, 2019 and July 14, 2020; and (ii) pursuant to the Securities Act of 1933 for misstatements in connection with it
Sep 24, 2020 04:15 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “the Company”) (NASDAQ:
Sep 24, 2020 04:00 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of NextCure, Inc. (NXTC) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ:
Sep 24, 2020 12:00 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NextCure, Inc. (NXTC) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC): (a) securities between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (b) common stock pursuant or traceable to the Company’s Novembe
Sep 24, 2020 11:30 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of NextCure, Inc. (NXTC) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ:
Sep 24, 2020 10:21 am ET
NXTC LOSSES ALERT: Bernstein Liebhard is Investigating NextCure Inc. For Violations of the Securities Laws
Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of NextCure Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) resulting from allegations that NextCure might have issued misleading information to the investing public.
Sep 23, 2020 04:15 pm ET
NEXTCURE, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern Distri
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) in the United States District Court for the Southern District of...
Sep 23, 2020 12:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ:
Sep 23, 2020 09:03 am ET
NXTC INVESTOR ALERT: Bernstein Liebhard is Investigating NextCure Inc. For Violations of the Securities Laws
Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of NextCure Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) resulting from allegations that NextCure might have issued misleading information to the investing public.
Sep 22, 2020 07:55 pm ET
NXTC EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against NextCure, Inc. – NXTC
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for NextCure investors under the federal securities laws.
Sep 22, 2020 07:00 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ:
Sep 22, 2020 05:03 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) investors concerning the Company’s possible violations of federal securities laws.
Sep 22, 2020 04:41 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against NextCure, Inc. (NXTC)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) in the United States District Court for the Southern District of New York on behalf of those who...
Sep 22, 2020 12:36 pm ET
NextCure Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) to determine whether the Company engaged in securities fraud or other unlawful business...
Sep 22, 2020 11:17 am ET
SHAREHOLDER ALERT: NextCure, Inc. Sued for Violations of the Federal Securities Laws; Investors Who Lost Money Should Contact Block & Leviton LLP
On July 13, 2020, NextCure, Inc. (NASDAQ: NXTC) shocked the markets when it announced that it no longer planned to advance the monotherapy trial for its lead product candidate, NC318, in non-small cell lung cancer and ovarian cancer. On the same...
Sep 21, 2020 08:54 pm ET
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against NextCure Inc.
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against NextCure, Inc. (“NextCure” or the “Company”), certain directors and officers of the Company, and the underwriters of NextCure’s Nove
Sep 14, 2020 04:05 pm ET
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G....
Sep 08, 2020 08:05 am ET
NextCure to Present at Morgan Stanley Virtual 18th Annual Global Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Aug 06, 2020 04:03 pm ET
NextCure Reports Second Quarter 2020 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2020 financial...
Aug 05, 2020 08:05 am ET
NextCure to Present at BTIG Virtual Biotechnology Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Jul 15, 2020 11:45 am ET
Scott+Scott Attorneys at Law LLP Announces Investigation into NextCure, Inc. (NXTC)
NEW YORK, July 15, 2020 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) or certain of its officers and directors violated federal securities laws.  If you purchased NextCure securities pursuant and/or traceable to NextCure's offering in November 2019 or have otherwise suffered a loss, realized or unrealized, you are encouraged to contact Scott+Scott attorney Jonathan Zimmerman at (888) 398-9312 for more information.
Jul 13, 2020 06:05 am ET
NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an interim update for the...
Jul 07, 2020 04:05 pm ET
NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2...
May 29, 2020 08:05 am ET
NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of biomarker...
May 07, 2020 05:10 pm ET
NextCure Reports First Quarter 2020 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2020 financial...
May 06, 2020 08:05 am ET
NextCure to Present at BofA Securities Virtual Health Care Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Apr 13, 2020 07:05 am ET
NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the company's...
Apr 08, 2020 07:05 am ET
NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Mar 30, 2020 07:05 am ET
NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Garry...
Mar 12, 2020 05:00 pm ET
NextCure Reports Fourth Quarter and Full Year 2019 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year...
Feb 25, 2020 08:05 am ET
NextCure to Present at the 40th Annual Cowen Health Care Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Feb 18, 2020 08:05 am ET
NextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the...
Jan 06, 2020 04:10 pm ET
NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present...
Nov 26, 2019 08:05 am ET
NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present...
Nov 19, 2019 04:05 pm ET
NextCure Announces Closing of Public Offering
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its public...
Nov 14, 2019 10:10 pm ET
NextCure Announces Pricing of Public Offering of Common Stock
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its public...
Nov 12, 2019 04:18 pm ET
NextCure Announces Proposed Public Offering of Common Stock
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced a proposed public offering of...
Nov 12, 2019 08:05 am ET
NextCure Reports Third Quarter 2019 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2019 financial...
Nov 09, 2019 05:05 pm ET
NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that updated clinical results...
Nov 04, 2019 08:05 am ET
NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing next-generation immunomedicines for cancer and other immune-related diseases, today announced that the company will host and webcast an event with...
Oct 02, 2019 07:30 am ET
NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the promotion of Timothy...
Oct 01, 2019 06:20 pm ET
NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical data from the...
Sep 03, 2019 04:05 pm ET
NextCure to Present at Morgan Stanley 17th Annual Global Healthcare Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present...
Aug 12, 2019 04:05 pm ET
NextCure Reports Second Quarter 2019 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2019 financial...
Jun 10, 2019 04:05 pm ET
NextCure Reports First Quarter 2019 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2019 financial...
May 13, 2019 04:05 pm ET
NextCure Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its initial...
May 08, 2019 08:46 pm ET
NextCure Announces Pricing of Initial Public Offering of Common Stock
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its initial...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.